Roche's RoActemra beats leading rival Humira in RA study; other news from EULAR

7 June 2012

Swiss drug major Roche (ROG: SIX) yesterday released new data from the ADACTA study which showed that adult rheumatoid arthritis (RA) patients who received its RoActemra (tocilizumab) as single-agent therapy (without other DMARDs) experienced a significantly greater improvement in disease activity (DAS28 score reduction) after 24 weeks compared to patients who received adalimumab as single-agent therapy.

Results from ADACTA showed that after 24 weeks of treatment patients with severe active RA and intolerance or inadequate response to MTX:

• achieved a mean improvement in disease activity (DAS28 score reduction) of 3.3 with RoActemra versus 1.8 with adalimumab;
• had a DAS28 remission rate of 40% with RoActemra versus 11% with adalimumab (DAS28 <2.6); and
• achieved ACR20, 50 and 702 responses of 65%, 47% and 33% with RoActemra versus 49%, 28% and 18% with adalimumab

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical